Molecular Pharmacology and Physiology
USF Health � College of Medicine
Login here to update your profile  
My Profile

David Morgan , Ph.D.
CEO, Byrd Alzheimer's Institute
Administrative Appointment: Division Director
Primary Department: COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

Distinguished Professor
COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY
profile Image
Contacts
Email: scientist.dave@gmail.com
Phone: (813) 974-3949
Office: ALZ, 406
Mailing address Alzheimer Institute ,4001 E. Fletcher Ave
Tampa, FL 33613
View My C.V.
 
Education
  • PHD, Neurobiology, Northwestern University , Evanston, United States - 1981.
    		•
  • M.S., Neurobiology, Northwestern University ,USA - 1978.
    		•
  • B.A., Philosophy/Psychology, Northwestern University ,USA - 1974.
    		•
     
    Interdisciplinary & Emerging Signature Programs
    Neuroscience, Allergy, Immunology & Infectious Disease, Biomedical Engineering & Nanomedicine.
     
    Research Summary

    Fundamental changes in aging brain and age related neurological disorders Role of astrocytes and microglial cells in the brains reaction to injury . Development of animal models for age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's disease Identification of the mechanisms leading to neuron loss in neurodegenerative disorders. Testing of therapeutic agents addressing the mechanisms of neurotoxicity in age-related neurodegenerative disorders

     
    Links
    Personal Page:   http://health.usf.edu/byrd/index.htm
    Lab Link:  http://hsc.usf.edu/medicine/pharmacology/dmmg/index.htm


    Selected Publications
  • Morgan, D.Diamond, DM.Gottschall, PE.Ugen, KE.Dickey, C.Hardy, J.Duff, K.Jantzen, P.DiCarlo, G.Wilcock, D.Connor, K.Hatcher, J.Hope, C.Gordon, M.Arendash, GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815): 982-5, .
  • Gordon, MN.King, DL.Diamond, DM.Jantzen, PT.Boyett, KV.Hope, CE.Hatcher, JM.DiCarlo, G.Gottschall, WP.Morgan, D.Arendash, GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of aging. 22(3): 377-85, .
  • Duff, K.Eckman, C.Zehr, C.Yu, X.Prada, CM.Perez-tur, J.Hutton, M.Buee, L.Harigaya, Y.Yager, D.Morgan, D.Gordon, MN.Holcomb, L.Refolo, L.Zenk, B.Hardy, J.Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383(6602): 710-3, 1996.
  • Holcomb, L.Gordon, MN.McGowan, E.Yu, X.Benkovic, S.Jantzen, P.Wright, K.Saad, I.Mueller, R.Morgan, D.Sanders, S.Zehr, C.O'Campo, K.Hardy, J.Prada, CM.Eckman, C.Younkin, S.Hsiao, K.Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature medicine. 4(1): 97-100, 1998.
  • Arendash, GW.King, DL.Gordon, MN.Morgan, D.Hatcher, JM.Hope, CE.Diamond, DM. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain research. 891(1-2): 42-53, 2001.
  • Morgan, D.Keller, RK. What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 4(3): 257-60, 2002.
  • Jantzen, PT.Connor, KE.DiCarlo, G.Wenk, GL.Wallace, JL.Rojiani, AM.Coppola, D.Morgan, D.Gordon, MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(6): 2246-54, 2002.
  • Gordon, MN.Holcomb, LA.Jantzen, PT.DiCarlo, G.Wilcock, D.Boyett, KW.Connor, K.Melachrino, J.O'Callaghan, JP.Morgan, D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental neurology. 173(2): 183-95, 2002.
  • Austin, L.Arendash, GW.Gordon, MN.Diamond, DM.DiCarlo, G.Dickey, C.Ugen, K.Morgan, D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behavioral neuroscience. 117(3): 478-84, 2003.
  • Wilcock, DM.DiCarlo, G.Henderson, D.Jackson, J.Clarke, K.Ugen, KE.Gordon, MN.Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(9): 3745-51, 2003.
  • Morgan, D. Antibody therapy for Alzheimer's disease. Expert review of vaccines. 2(1): 53-9, 2003.
  • Dickey, CA.Loring, JF.Montgomery, J.Gordon, MN.Eastman, PS.Morgan, D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(12): 5219-26, 2003.
  • Morgan, D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochemical research. 28(7): 1029-34, 2003.
  • Kassed, CA.Butler, TL.Navidomskis, MT.Gordon, MN.Morgan, D.Pennypacker, KR. Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury. Brain research. Molecular brain research. 110(1): 152-7, 2003.
  • Herber, DL.Roth, LM.Wilson, D.Wilson, N.Mason, JE.Morgan, D.Gordon, MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Experimental neurology. 190(1): 245-53, 2004.
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Subbarao, S.Freeman, MJ.Gordon, MN.Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of neuroinflammation. 1(1): 24, 2004.
  • Dickey, CA.Gordon, MN.Mason, JE.Wilson, NJ.Diamond, DM.Guzowski, JF.Morgan, D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. Journal of neurochemistry. 88(2): 434-42, 2004.
  • Wilcock, DM.Munireddy, SK.Rosenthal, A.Ugen, KE.Gordon, MN.Morgan, D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiology of disease. 15(1): 11-20, 2004.
  • Garcia, MF.Gordon, MN.Hutton, M.Lewis, J.McGowan, E.Dickey, CA.Morgan, D.Arendash, GW. The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport. 15(1): 73-7, 2004.
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Levkowitz, G.Subbarao, S.Alamed, J.Wilson, D.Wilson, N.Freeman, MJ.Gordon, MN.Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24(27): 6144-51, 2004.
  • Dickey, CA.De Mesquita, DD.Morgan, D.Pennypacker, KR. Induction of memory-associated immediate early genes by nerve growth factor in rat primary cortical neurons and differentiated mouse Neuro2A cells. Neuroscience letters. 366(1): 10-4, 2004.
  • Townsend, KP.Shytle, DR.Bai, Y.San, N.Zeng, J.Freeman, M.Mori, T.Fernandez, F.Morgan, D.Sanberg, P.Tan, J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. Journal of neuroscience research. 78(2): 167-76, 2004.
  • Herber, DL.Severance, EG.Cuevas, J.Morgan, D.Gordon, MN. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 52(10): 1367-76, 2004.
  • Townsend, KP.Town, T.Mori, T.Lue, LF.Shytle, D.Sanberg, PR.Morgan, D.Fernandez, F.Flavell, RA.Tan, J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. European journal of immunology. 35(3): 901-10, 2005.
  • Morgan, D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neuro-degenerative diseases. 2(5): 261-6, 2005.
  • Rezai-Zadeh, K.Shytle, D.Sun, N.Mori, T.Hou, H.Jeanniton, D.Ehrhart, J.Townsend, K.Zeng, J.Morgan, D.Hardy, J.Town, T.Tan, J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(38): 8807-14, 2005.
  • Dickey, CA.Gordon, MN.Wilcock, DM.Herber, DL.Freeman, MJ.Morgan, D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC neuroscience. 6(1): 7, 2005.
  • Morgan, D.Gordon, MN.Tan, J.Wilcock, D.Rojiani, AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of neuropathology and experimental neurology. 64(9): 743-53, 2005.
  • Morgan, D. Immunotherapy for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 9(3 Suppl): 425-32, 2006.
  • Herber, DL.Maloney, JL.Roth, LM.Freeman, MJ.Morgan, D.Gordon, MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia. 53(4): 382-91, 2006.
  • Wilcock, DM.Gordon, MN.Morgan, D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature protocols. 1(3): 1591-5, 2006.
  • Carty, NC.Wilcock, DM.Rosenthal, A.Grimm, J.Pons, J.Ronan, V.Gottschall, PE.Gordon, MN.Morgan, D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of neuroinflammation. 3(): 11, 2006.
  • Morgan, D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochemistry international. 49(2): 190-4, 2006.
  • Wilcock, DM.Alamed, J.Gottschall, PE.Grimm, J.Rosenthal, A.Pons, J.Ronan, V.Symmonds, K.Gordon, MN.Morgan, D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(20): 5340-6, 2006.
  • Li, Q.Gordon, M.Cao, C.Ugen, KE.Morgan, D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC neuroscience. 8(): 22, 2007.
  • Karlnoski, R.Wilcock, D.Dickey, C.Ronan, V.Gordon, MN.Zhang, W.Morgan, D.Taglialatela, G. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of disease. 25(1): 179-88, 2007.
  • Wilcock, DM.Jantzen, PT.Li, Q.Morgan, D.Gordon, MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 144(3): 950-60, 2007.
  • Morgan, D. Amyloid, memory and neurogenesis. Experimental neurology. 205(2): 330-5, 2007.
  • Nikolic, WV.Bai, Y.Obregon, D.Hou, H.Mori, T.Zeng, J.Ehrhart, J.Shytle, RD.Giunta, B.Morgan, D.Town, T.Tan, J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proceedings of the National Academy of Sciences of the United States of America. 104(7): 2507-12, 2007.
  • Herber, DL.Mercer, M.Roth, LM.Symmonds, K.Maloney, J.Wilson, N.Freeman, MJ.Morgan, D.Gordon, MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2(2): 222-31, 2007.
  • Carty, NC.Nash, K.Lee, D.Mercer, M.Gottschall, PE.Meyers, C.Muzyczka, N.Gordon, MN.Morgan, D. Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Abeta Deposits in APP + PS1 Transgenic Mice. Molecular therapy : the journal of the American Society of Gene Therapy. (): , 2008.
  • Karlnoski, RA.Rosenthal, A.Alamed, J.Ronan, V.Gordon, MN.Gottschall, PE.Grimm, J.Pons, J.Morgan, D. Deglycosylated Anti-Abeta Antibody Dose-Response Effects on Pathology and Memory in APP Transgenic Mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. (): , 2008.
  • Li, Q.Gordon, M.Etienne, MA.Hammer, RP.Morgan, D. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell transplantation. 17(4): 397-408, 2008.
  • Morgan, D.Gordon, MN. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behavioral neuroscience. 122(3): 730-2, 2008.
  • Dickey, CA.Koren, J.Zhang, YJ.Xu, YF.Jinwal, UK.Birnbaum, MJ.Monks, B.Sun, M.Cheng, JQ.Patterson, C.Bailey, RM.Dunmore, J.Soresh, S.Leon, C.Morgan, D.Petrucelli, L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America. 105(9): 3622-7, 2008.
  • Morgan, D.Munireddy, S.Alamed, J.DeLeon, J.Diamond, DM.Bickford, P.Hutton, M.Lewis, J.McGowan, E.Gordon, MN. Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. Journal of Alzheimer's disease : JAD. 15(4): 605-14, 2008.
  • Karlnoski, RA.Rosenthal, A.Kobayashi, D.Pons, J.Alamed, J.Mercer, M.Li, Q.Gordon, MN.Gottschall, PE.Morgan, D. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(15): 4964-71, 2009.
  • Jinwal, UK.Miyata, Y.Koren, J.Jones, JR.Trotter, JH.Chang, L.O'Leary, J.Morgan, D.Lee, DC.Shults, CL.Rousaki, A.Weeber, EJ.Zuiderweg, ER.Gestwicki, JE.Dickey, CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(39): 12079-88, 2009.
  • Morgan, D.Landreth, G.Bickford, P. The promise and perils of an Alzheimer disease vaccine: a video debate. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 4(1): 1-3, 2009.
  • Dickey, C.Kraft, C.Jinwal, U.Koren, J.Johnson, A.Anderson, L.Lebson, L.Lee, D.Dickson, D.de Silva, R.Binder, LI.Morgan, D.Lewis, J. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. The American journal of pathology. 174(1): 228-38, 2009.
  • Lord, A.Englund, H.Söderberg, L.Tucker, S.Clausen, F.Hillered, L.Gordon, M.Morgan, D.Lannfelt, L.Pettersson, FE.Nilsson, LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The FEBS journal. 276(4): 995-1006, 2009.
  • Morgan, D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS & neurological disorders drug targets. 8(1): 7-15, 2009.
  • Zhu, Y.Obregon, D.Hou, H.Giunta, B.Erhart, J.Fernandez, F.Mori, T.Nikolic, W.Zhao, Y.Morgan, D.Town, T.Tan, J. Mutant presenilin-1 deregulated peripheral immunity exacerbates alzheimer-like pathology. Journal of cellular and molecular medicine. (): , 2009.
  • Carty, N.Lee, D.Dickey, C.Ceballos-Diaz, C.Jansen-West, K.Golde, TE.Gordon, MN.Morgan, D.Nash, K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1): 144-53, 2010.
  • Lee, DC.Rizer, J.Selenica, ML.Reid, P.Kraft, C.Johnson, A.Blair, L.Gordon, MN.Dickey, CA.Morgan, D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of neuroinflammation. 7(): 56, 2010.
  • Li, QY.Gordon, MN.Chackerian, B.Alamed, J.Ugen, KE.Morgan, D. Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 5(1): 133-42, 2010.
  • Lebson, L.Nash, K.Kamath, S.Herber, D.Carty, N.Lee, DC.Li, Q.Szekeres, K.Jinwal, U.Koren, J.Dickey, CA.Gottschall, PE.Morgan, D.Gordon, MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29): 9651-8, 2010.
  • Ajmo, JM.Bailey, LA.Howell, MD.Cortez, LK.Pennypacker, KR.Mehta, HN.Morgan, D.Gordon, MN.Gottschall, PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. Journal of neurochemistry. 113(3): 784-95, 2010.
  • Morgan, D. Immunotherapy for Alzheimer's disease. Journal of internal medicine. 269(1): 54-63, 2011.
  • Lee, DC.Rizer, J.Hunt, JB.Selenica, ML.Gordon, MN.Morgan, D. Experimental manipulations of microglia in mouse models of Alzheimer's pathology. Activation reduces amyloid but hastens tau pathology. Neuropathology and applied neurobiology. (): , 2012.
  • Selenica, ML.Brownlow, M.Jimenez, JP.Lee, DC.Pena, G.Dickey, CA.Gordon, MN.Morgan, D. Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neuro-degenerative diseases. (): , 2012.
  • Nash, KR.Lee, DC.Hunt, JB.Morganti, JM.Selenica, ML.Moran, P.Reid, P.Brownlow, M.Guang-Yu Yang, C.Savalia, M.Gemma, C.Bickford, PC.Gordon, MN.Morgan, D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of aging. (): , 2013.

    • Positions Held
  • CEO / Director (Byrd Alzheimer Institute, USF College of Medicine 2009 - Present)
  • Director (Signature Program in Neuroscience, USF College of Medicine 2006 - Present)
  • Distinguished Professor (Dept. of Molec. Pharm & Physiol, University of South Florida 1998 - Present)


    • Memberships
  • ASNTR (Councilor, 1998 - Present)
  • Society for Neuroscience (member, 1980 - Present)
  • AAAS (member, 1938 - Present)


    • Awards/Honors
  • Distinguished Health Professor (University of South Florida - 2010)
    		•
  • USF President's Award for Faculty Excellence (University of South Florida - 2002)
    		•
  • Established Investigator Award (American Heart Association - 1989)
    		•


    Grants
  • IMMUNOTHERAPY AGAINST TAUOPATHY IN A TRANSGENIC MOUSE MODEL ($315,209.00, 05/15/2011-02/29/2016)
  • IMMUNOTHERAPY AGAINST TAUOPATHY IN A TRANSGENIC MOUSE MODEL ($346,059.00, 05/15/2011-02/29/2016)
  • IMMUNOTHERAPY AGAINST TAUOPATHY IN A TRANSGENIC MOUSE MODEL ($341,971.00, 05/15/2011-02/29/2016)
  • KETOGENSIS AND ALZHEIMER'S PATHOLOGY ($60,000.00, 09/01/2010-08/31/2013)
  • KETOGENSIS AND ALZHEIMER'S PATHOLOGY ($70,000.00, 09/01/2010-08/31/2013)
  • KETOGENSIS AND ALZHEIMER'S PATHOLOGY ($70,000.00, 09/01/2010-08/31/2013)
  • PROPOSAL TO TEST NEUROGENIC AGENT NSI-189 IN APP+PS1 TRANSGENIC MICE ($53,830.00, 07/12/2010-07/11/2013)
  • INTRACRANIAL ADMINISTRATION OF IVIG IN AMYLOID DEPOSITING MICE ($100,948.00, 06/07/2012-06/06/2013)
  • Multiple Glial Activation States in aged Brain ($170,000.00, 07/01/2006-06/30/2011)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($272,569.00, 02/15/2006-01/31/2011)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($275,322.00, 02/15/2006-01/31/2011)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($275,322.00, 02/15/2006-01/31/2011)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($280,941.00, 02/15/2006-01/31/2011)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($289,331.00, 02/15/2006-01/31/2011)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($389,208.00, 09/15/2005-06/30/2010)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($408,989.00, 09/15/2005-06/30/2010)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($30,760.00, 09/15/2005-06/30/2010)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($358,890.00, 09/15/2005-06/30/2010)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($402,129.00, 09/15/2005-06/30/2010)
  • AAV GENE THERAPY FOR ALZHEIMER'S DISEASE ($368,024.00, 09/15/2005-06/30/2010)
  • DIGITAL MICSCOPIC IMAGE SCANNING SYSTEM ($221,200.00, 05/01/2009-04/30/2010)
  • EFFECTS OF CBAT CELLS ON AMYLOID DEPOSITION IN TRANSGENIC MICE ($43,174.00, 12/04/2007-12/03/2008)
  • TESTING OF COMPOUND A IN TRANSGENIC MICE ($10,150.00, 01/01/2006-12/31/2007)
  • VACCINES AGAINST AMYLOID-BETA USING CONJUGATED VIRUS-LIKE PARTICLES ($27,500.00, 09/01/2006-08/31/2007)
  • BENJAMIN INTEREST EARNING ACCOUNT ($43,000.00, 07/01/1996-06/30/2007)
  • TESTING OF COMPOUND A IN TRANSGENIC MICE ($114,500.00, 01/01/2006-12/31/2006)
  • ANTI-AMYLOID GENE THERAPY FOR ALZHEIMER'S DISEASE ($89,600.00, 06/30/2004-06/30/2006)
  • PROTOCOL #CHF5022 ($21,750.00, 12/01/2003-08/30/2005)
  • ANTI-AMYLOID GENE THERAPY FOR ALZHEIMER'S DISEASE ($89,600.00, 06/30/2004-06/29/2005)
  • STUDIES TO EVALUATE PCL-015 AND FSR-488 FOR ANTI-AMYLOID ACTIVITY IN APP+PS1 TRANSGENIC MOUSE MODEL OF AMYLOID DEPOSITION ($59,084.00, 08/01/2004-04/30/2005)
  • PROTOCOL #CHF5022 ($27,753.00, 12/01/2003-11/30/2004)
  • A VACCINE APPROACH TO THE TREATMENT OF PARKINSON'S DISEASE ($158,750.00, 02/01/2002-01/31/2004)
  • A VACCINE APPROACH TO THE TREATMENT OF PARKINSON'S DISEASE ($170,000.00, 02/01/2002-01/31/2004)
  • REGULATION OF INFLAMMATION IN TRANSGENIC MICE ($173,756.00, 03/14/2002-06/30/2003)
  • A VACCINE APPROACH TO THE TREATMENT OF PARKINSON'S DISEASE ($150,000.00, 07/01/2001-06/30/2003)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($452,259.00, 08/15/2000-06/30/2003)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($447,108.00, 08/15/2000-06/30/2003)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($449,645.00, 08/15/2000-06/30/2003)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($444,643.00, 08/15/2000-06/30/2003)
  • BENJAMIN INTEREST EARNING ACCOUNT ($24,000.00, 07/01/1996-06/30/2003)
  • BENJAMIN INTEREST EARNING ACCOUNT ($21,100.00, 07/01/1996-06/30/2003)
  • BENJAMIN INTEREST EARNING ACCOUNT ($29,500.00, 07/01/1996-06/30/2003)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($79,750.00, 08/15/2000-06/30/2002)
  • FUNCTIONAL CONSEQUENCES OF VACCINATION IN AD TG MICE ($362,500.00, 08/15/2000-06/30/2002)
  • BEHAVIORAL AND PATHOLOGICAL ANALYSIS OF TRANSGENIC MICE-BLUEBERRY TREATMENT ($18,450.00, 04/30/2000-09/30/2001)


    • Lectures
  • "Aging and Alzheimers Disease" American Federation for Aging research Fundraiser. FL, United States - 2010.
  • "Immunotherapeutic Approaches to Reducing Brain Amyloid" Alzheimers Research Trust Annual Meeting. United Kingdom - 2010.
  • "Immunotherapeutic Approaches to Lowering Abeta" Lundbeck Pharmaceuticals. Denmark - 2010.
  • "Biology of Alzhemers Disease" Lifelong Learning seminar. FL, United States - 2010.
  • "Measurement of Tau Pathology in Transgenic Mice" Alzheimers Drug Development Foundation. NY, United States - 2010.
  • "Advances in Alzheimers Research and Prevention" Tampa FL. FL, United States - 2010.
  • "Gene Therapy for Alzheimers Disease" University of Linkoeping. Sweden - 2010.
  • "Immunotherapy for Alzheimers Disease" Axel Key Symposium, Karolinska Institute. Sweden - 2010.
  • "Specificity f antibodies directed against Aß in mouse models of amyloid deposition" Bioarctic Inc. Sweden - 2010.
  • "Alzheimers disease in Florida" Us Against Alzheimers Press Breifing. FL, United States - 2010.
  • "Update on the USF Health Byrd Alzheimer Institute" Tampa Exchange Club. FL, United States - 2010.
  • "Drug Development for Alzheimers Disease" NIA Advisory Panel. MD, United States - 2010.
  • "Targetted Therapeis for Alzheimers Disease" Tampa Rotary Club. FL, United States - 2009.
  • "Molecular Therapeutic Approaches to Lowering Brain Amyloid; Immunotherapy and Gene Therapy" University of Kentucky. KY, United States - 2009.
  • "Immunotherapy and Gene Therapy Against Brain Amyloid" Northwestern University. IL, United States - 2009.
  • "Modulating Aß with monocyte gene therapy" 9th International AD/PD Meeting. Czech Republic - 2009.
  • "New Advances in Antibodies and Genes to Treat Alzheimers Disease" Museum of Science and Industry. FL, United States - 2009.
  • "Advances to treat Alzheimers Disease" Florida Elder Law Conference. FL, United States - 2009.
  • "Biomedical Ethics in the 21st Century" Moffitt Cancer Center. FL, United States - 2009.
  • "Molecular Approaches to Lowering Brain Amyloid; Immunotherapy and Gene Therapy" . Linkoping Sweden. Sweden - 2009.
  • "Immunotherapy Against Aß as a Treatment for Alzheimers Disease" Conference on Neuroimmunology. Finland - 2009.
  • "Classical versus Alternative Activation of Microglia in Aging and Alzheimers Disease" Kuopio Finland. Finland - 2009.
  • "Molecular Approaches to Lowering Brain Amyloid" Georgetown University. DC, United States - 2009.
  • "new Developments in Alzheimers Disease" Exchange Club. FL, United States - 2009.
  • "Research Developments at the Byrd Alzheimer Institute" Rotary Club, Plant City FL. FL, United States - 2009.
  • "Molecular Therapeutic for Alzheimers Disease " Third International Brain Conference. FL, United States - 2009.
  • "Molecular Therapeutics for Alzheimers Disease" Texas A&M University. TX, United States - 2009.
  • "Immunotherapy to remove amyloid deposits. Potential as a therapeutic and usefulness as a research tool" University of Texas Health Sciences Center. TX, United States - 2008.
  • "Immunotherapy for Alzheimer's disease" Columbia University College of Medicine. NY, United States - 2008.
  • "Therapeutic Reduction of Beta-Amyloid in Transgenic Mice" Sils Maria Conference. Switzerland - 2008.
  • "Antibody mediated clearance of amyloid deposits and restoration of memory" New York Academy of Science. NY, United States - 2008.
  • "Microglial signal transduction mechanisms" International Congress on Alzheimers Dementia. IL, United States - 2008.
  • "Passive Immunotherapies as an Approach to Disease Modification in Alzheimers Disease" Pfizer Educational Dinner Symposium. IL, United States - 2008.
  • "Immunotherapy as a treatment for Alzheimers disease" Federation of European Neurological Societies. Spain - 2008.
  • "Amyloid immunotherapy" University of Southern California. CA, United States - 2008.
  • "Role of microglia/macrophages" University of Southern California. CA, United States - 2008.
  • "New Models of Drug Discovery Linking Academia and Industry" Hampton Roads Chamber of Commerce. VA, United States - 2008.
  • "Immunotherapeutic approaches to lowering amyloid in AD" UK-US International Alzheimers Disease Symposium. FL, United States - 2008.
  • "Development of Immunotherapy for Alzheimer's Disease" University of Central Florida. FL, United States - 2008.
  • "From Tribulations to Trials" University of Central Florida. FL, United States - 2008.
  • "See CV 5 USA; 3 Intntl" Many. FL, United States - 2007.

    • Profile last modified on 01/22/2013